<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040298</url>
  </required_header>
  <id_info>
    <org_study_id>ReBUILD</org_study_id>
    <nct_id>NCT02040298</nct_id>
  </id_info>
  <brief_title>Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis</brief_title>
  <acronym>ReBUILD</acronym>
  <official_title>A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess clemastine as a remyelinating agent in patients&#xD;
      with relapsing forms of multiple sclerosis. The study will also evaluate the tolerability of&#xD;
      clemastine, originally approved as first-generation antihistamine, in patients with multiple&#xD;
      sclerosis. Study procedures will include assessments for evidence of remyelination in the&#xD;
      anterior visual pathway and in the brain using electrophysiologic techniques and magnetic&#xD;
      resonance imaging. The study will also assess the robustness and stability of this clinical&#xD;
      effect in patients taking clemastine for up to 3 months. Patients in this study can remain on&#xD;
      their standard disease modifying treatment during the course of the study. However, patients&#xD;
      cannot participate in any other investigational new drug research study concurrently.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Full Field Visual Evoked Potential (VEP)</measure>
    <time_frame>Treatment start to treatment end, up to 3 months.</time_frame>
    <description>The primary objective is to evaluate the efficacy of Clemastine relative to placebo for reducing P100 latencies on full field transient pattern reversal visual evoked potentials.Visual evoked potentials (VEP) are used primarily to measure the functional integrity of the visual pathways from the retina to the visual cortex of the brain. VEP latencies were collected at Baseline, Month 1, Month 3, and Month 5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Clemastine in Multiple Sclerosis (MS) Patients</measure>
    <time_frame>Treatment start to treatment end, up to 3 months.</time_frame>
    <description>Will demonstrate the tolerability of Clemastine in this population. This will include special focus with regards to fatigue as this is a major symptom for patients suffering from multiple sclerosis.This will be assessed by administering a fatigue questionnaire called the Multidimensional Assessment of Fatigue (MAF) at all four visits throughout the study. MAF scale range is 0-50. Lower scores indicate lower levels of fatigue and higher scores indicate higher levels of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myelin Water Fraction (MWF) and Magnetization Transfer Ratios (MTR)</measure>
    <time_frame>Treatment start to treatment end, up to 3 months.</time_frame>
    <description>To evaluate the efficacy of Clemastine relative to placebo in increasing magnetization transfer ratios derived from magnetic resonance imaging (MRI) of the brain during the period of exposure to active treatment.&#xD;
To evaluate the efficacy of Clemastine relative to placebo at reducing radial diffusivity derived from diffusion tensor imaging as assessed by magnetic resonance imaging (MRI) during the period of exposure to active medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS) Score</measure>
    <time_frame>Start of treatment to end of treatment, up to 3 months</time_frame>
    <description>To evaluate the efficacy of Clemastine relative to placebo in reducing the EDSS score at 90 days compared to placebo (Group A) &amp; at 150 days compared to day 90 (Group B). EDSS is an ordinal scale for assessing neurological impairment of MS based on a neurological examination. It consists of scores in each of seven functional systems (FS) &amp; an ambulation score that are then combined to determine the EDSS [ranging from 0 (normal) to 10 (death due to MS)]. The FSs are the Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel &amp; Bladder, &amp; Cerebral functions. FSs &amp; EDSS steps assessed in a standardized manner. EDSS is a widely used &amp;accepted instrument to evaluate disability status at a given time &amp; longitudinally, to assess disability progression in clinical studies in MS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Creatinine Level</measure>
    <time_frame>Baseline, 1 month, 3 month, 5 month</time_frame>
    <description>Blood sample will be collected at each visit to evaluate health status...</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Triglyceride Level</measure>
    <time_frame>Baseline, 1 month, 3 month, 5 month</time_frame>
    <description>Blood sample will be collected at each visit to evaluate health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vitamin B-12 Level</measure>
    <time_frame>Baseline, 1 month, 3 month, 5 month</time_frame>
    <description>Blood sample will be collected at each visit to evaluate health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Human Chorionic Gonadotropin (hCG) Level in Female Patients of Childbearing Potential</measure>
    <time_frame>Baseline, 1 month, 3 month, 5 month</time_frame>
    <description>Blood and urine sample will be collected to assess pregnancy status of all female participants of child bearing potential.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>3 months Clemastine, 2 months Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4mg clemastine twice daily for first 3 months -- crossover -- equivalent quantity/frequency of placebo for last 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 months Placebo , 2 months Clemastine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo for first 3 months -- crossover -- 4mg clemastine twice daily for last 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clemastine</intervention_name>
    <description>4mg tablet twice daily</description>
    <arm_group_label>3 months Clemastine, 2 months Placebo</arm_group_label>
    <arm_group_label>3 months Placebo , 2 months Clemastine</arm_group_label>
    <other_name>Clemastine Fumarate,</other_name>
    <other_name>Tavist -1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice daily</description>
    <arm_group_label>3 months Clemastine, 2 months Placebo</arm_group_label>
    <arm_group_label>3 months Placebo , 2 months Clemastine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsing remitting Multiple Sclerosis by 2010 Revised McDonald Criteria&#xD;
&#xD;
          -  Age 18-60.&#xD;
&#xD;
          -  Latency delay &gt; 125 milliseconds on baseline full-field transient pattern reversal&#xD;
             visual evoked potential (VEP) in at least one eye (electrophysiological evidence of&#xD;
             demyelination)&#xD;
&#xD;
          -  Retinal nerve fiber layer (RNFL) &gt; 70 microns on Spectralis Domain Optical Coherence&#xD;
             Topography (SD-OCT) in the same eye meeting criteria for latency delay (sufficient&#xD;
             axons)&#xD;
&#xD;
          -  No optic neuritis in prior 6 months&#xD;
&#xD;
          -  Stable immunomodulatory therapy - no switch or planned switch in &gt; 6 months and no&#xD;
             change in doses in 30 days prior to screening&#xD;
&#xD;
          -  Use of appropriate contraception during period of trial (females of child bearing&#xD;
             potential)&#xD;
&#xD;
          -  Understand and sign informed consent.&#xD;
&#xD;
          -  Expanded disability status scale (EDSS) 0-6.0 (inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major ophthalmologic disease / Concomitant ophthalmologic disorders (e.g. diabetes,&#xD;
             macular degeneration, glaucoma, severe myopia , etc).&#xD;
&#xD;
          -  Myopia &gt; -7 Diopters (Severe myopia)&#xD;
&#xD;
          -  History of significant cardiac conduction block&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  Known optic neuritis in involved eye &gt; 5 years ago OR disease duration &gt; 15 years&#xD;
&#xD;
          -  Suicidal ideation or behaviour in 6 months prior to screening&#xD;
&#xD;
          -  Pregnancy, breastfeeding, or planning to become pregnant.&#xD;
&#xD;
          -  Involved with other study protocol simultaneously without prior approval. 9.&#xD;
             Concomitant use of Dalfampridine (4AP or diamino4AP) or any other formulation of 4AP&#xD;
             or diamino4AP.&#xD;
&#xD;
          -  Concomitant use of any other putative remyelinating therapy as determined by&#xD;
             investigator.&#xD;
&#xD;
          -  Treatment with corticosteroids within 30 days prior to screening&#xD;
&#xD;
          -  Prior treatment with total lymphoid irradiation, T cell or T cell receptor vaccination&#xD;
&#xD;
          -  Prior treatment with alemtuzumab, mitoxantrone, or cyclophosphamide&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 mg/dL; aspartate aminotransferase (AST), alanine&#xD;
             aminotransferase (ALT) or alkaline phosphatase &gt; 2 times the upper limit of normal&#xD;
&#xD;
          -  History of drug or alcohol abuse within the past year&#xD;
&#xD;
          -  Untreated vitamin B12 deficiency (as determined by B12 serological assessments and&#xD;
             metabolites including methylmalonic acid (MMA) and homocysteine) or untreated&#xD;
             hypothyroidism&#xD;
&#xD;
          -  Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic,&#xD;
             urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic,&#xD;
             psychiatric allergic, renal or other major diseases that in the PI's judgment may&#xD;
             affect interpretation of study results or patient safety.&#xD;
&#xD;
          -  History of or presence of clinically significant medical illness or laboratory&#xD;
             abnormality that, in the opinion of the investigator would preclude participation in&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari J. Green, MD, MCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Multiple Sclerosis Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://multiplesclerosis.ucsf.edu/research/rebuild</url>
    <description>ReBUILD trial description University of California, San Francisco Multiple Sclerosis Center</description>
  </link>
  <reference>
    <citation>Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler. 1999 Aug;5(4):251-9. Review.</citation>
    <PMID>10467384</PMID>
  </reference>
  <results_reference>
    <citation>Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2. Epub 2017 Oct 10.</citation>
    <PMID>29029896</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <results_first_submitted>May 21, 2018</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2021</results_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clemastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clemastine First, Then Placebo</title>
          <description>Participants first received Clemastine 4mg twice daily for 3 months. Then they received Placebo (matching Clemastine 4mg) twice daily for 2 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Clemastine</title>
          <description>Participants first received Placebo (matching Clemastine 4mg) twice daily for 3 months. Then they received Clemastine 4mg twice daily for 2 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (3 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (2 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clemastine First, Then Placebo</title>
          <description>Participants first received Clemastine 4mg tablet twice daily for 3 months, then they received Placebo (matching Clemastine 4mg) for 2 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Clemastine</title>
          <description>Participants first received Placebo (matching Clemastine 4mg) tablet twice daily for 3 months, then they received Clemastine 4mg twice daily for 2 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="10.8"/>
                    <measurement group_id="B2" value="40.0" spread="10.1"/>
                    <measurement group_id="B3" value="40.1" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="6.5"/>
                    <measurement group_id="B2" value="4.4" spread="3.6"/>
                    <measurement group_id="B3" value="5.1" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EDSS</title>
          <description>Expanded Disability Status Scale (EDSS) is an ordinal scale for assessing neurological impairment of MS based on a neurological examination. It consists of scores in each of seven functional systems (FS) and an ambulation score that are then combined to determine the EDSS [ranging from 0 (normal) to 10 (death due to MS)].</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="1.0"/>
                    <measurement group_id="B2" value="2.1" spread="1.2"/>
                    <measurement group_id="B3" value="2.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of optic neuritis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since optic neuritis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="3.4"/>
                    <measurement group_id="B2" value="4.9" spread="4.6"/>
                    <measurement group_id="B3" value="4.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VEP P100 latency</title>
          <description>Visual Evoked Potential (VEP); prominent positive deflection (P100)</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128.6" spread="11.6"/>
                    <measurement group_id="B2" value="126.8" spread="9.4"/>
                    <measurement group_id="B3" value="127.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OCT Retinal Nerve Fiber Layer (RNFL)</title>
          <description>Optical Coherence Tomography (OCT) Retinal Nerve Fiber Layer (RNFL)</description>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.2" spread="12.0"/>
                    <measurement group_id="B2" value="85.1" spread="7.9"/>
                    <measurement group_id="B3" value="86.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OCT Macular volume</title>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.05" spread="0.14"/>
                    <measurement group_id="B2" value="3.01" spread="0.11"/>
                    <measurement group_id="B3" value="3.03" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LCLA</title>
          <description>Low Contrast Letter Acuity (LCLA) is scored from 0-70. Higher scores are better.</description>
          <units>Number of letters read correctly</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.0" spread="8.4"/>
                    <measurement group_id="B2" value="21.6" spread="10.7"/>
                    <measurement group_id="B3" value="22.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SDMT</title>
          <description>Symbol Digit Modalities Test (SDMT) is scored 0-110. Higher scores are better.</description>
          <units>number of correct substitutions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="10.2"/>
                    <measurement group_id="B2" value="50.0" spread="11.1"/>
                    <measurement group_id="B3" value="50.9" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MAF</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.82" spread="12.39"/>
                    <measurement group_id="B2" value="20.43" spread="10.88"/>
                    <measurement group_id="B3" value="19.13" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6-min walk</title>
          <units>feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1742.40" spread="288.14"/>
                    <measurement group_id="B2" value="1741.76" spread="260.08"/>
                    <measurement group_id="B3" value="1742.08" spread="271.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25-foot walk</title>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.81" spread="0.67"/>
                    <measurement group_id="B2" value="4.10" spread="1.01"/>
                    <measurement group_id="B3" value="3.96" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myelin water fraction</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.55" spread="11.85"/>
                    <measurement group_id="B2" value="65.70" spread="12.98"/>
                    <measurement group_id="B3" value="66.62" spread="12.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MTR 25</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Brain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.39" spread="0.05"/>
                    <measurement group_id="B2" value="0.38" spread="0.03"/>
                    <measurement group_id="B3" value="0.39" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White matter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.54" spread="0.02"/>
                    <measurement group_id="B2" value="0.54" spread="0.02"/>
                    <measurement group_id="B3" value="0.54" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FA white matter</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.24" spread="0.02"/>
                    <measurement group_id="B2" value="0.24" spread="0.01"/>
                    <measurement group_id="B3" value="0.24" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Full Field Visual Evoked Potential (VEP)</title>
        <description>The primary objective is to evaluate the efficacy of Clemastine relative to placebo for reducing P100 latencies on full field transient pattern reversal visual evoked potentials.Visual evoked potentials (VEP) are used primarily to measure the functional integrity of the visual pathways from the retina to the visual cortex of the brain. VEP latencies were collected at Baseline, Month 1, Month 3, and Month 5.</description>
        <time_frame>Treatment start to treatment end, up to 3 months.</time_frame>
        <population>The data for 7 eyes did not meet criteria for inclusion in analysis (i.e., absent or unidentifiable waveforms.).</population>
        <group_list>
          <group group_id="O1">
            <title>Clemastine</title>
            <description>Participants who received clemastine 4mg twice daily in either the first 3 months or the last 2 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Placebo tablet (matching clemastine 4mg) twice daily in either the first 3 months or last 2 months of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Full Field Visual Evoked Potential (VEP)</title>
          <description>The primary objective is to evaluate the efficacy of Clemastine relative to placebo for reducing P100 latencies on full field transient pattern reversal visual evoked potentials.Visual evoked potentials (VEP) are used primarily to measure the functional integrity of the visual pathways from the retina to the visual cortex of the brain. VEP latencies were collected at Baseline, Month 1, Month 3, and Month 5.</description>
          <population>The data for 7 eyes did not meet criteria for inclusion in analysis (i.e., absent or unidentifiable waveforms.).</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VEP at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.8" spread="11.5"/>
                    <measurement group_id="O2" value="126.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEP change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.86" spread="6.85"/>
                    <measurement group_id="O2" value="1.50" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of Clemastine in Multiple Sclerosis (MS) Patients</title>
        <description>Will demonstrate the tolerability of Clemastine in this population. This will include special focus with regards to fatigue as this is a major symptom for patients suffering from multiple sclerosis.This will be assessed by administering a fatigue questionnaire called the Multidimensional Assessment of Fatigue (MAF) at all four visits throughout the study. MAF scale range is 0-50. Lower scores indicate lower levels of fatigue and higher scores indicate higher levels of fatigue.</description>
        <time_frame>Treatment start to treatment end, up to 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clemastine</title>
            <description>Participants who received clemastine 4mg tablet twice a day either the first 3 months or last 2 months of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Placebo (matching clemastine 4mg) twice a day in either the first 3 months or last 2 months of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Clemastine in Multiple Sclerosis (MS) Patients</title>
          <description>Will demonstrate the tolerability of Clemastine in this population. This will include special focus with regards to fatigue as this is a major symptom for patients suffering from multiple sclerosis.This will be assessed by administering a fatigue questionnaire called the Multidimensional Assessment of Fatigue (MAF) at all four visits throughout the study. MAF scale range is 0-50. Lower scores indicate lower levels of fatigue and higher scores indicate higher levels of fatigue.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAF at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="10.9"/>
                    <measurement group_id="O2" value="18.8" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAF change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="6.8"/>
                    <measurement group_id="O2" value="-0.4" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myelin Water Fraction (MWF) and Magnetization Transfer Ratios (MTR)</title>
        <description>To evaluate the efficacy of Clemastine relative to placebo in increasing magnetization transfer ratios derived from magnetic resonance imaging (MRI) of the brain during the period of exposure to active treatment.&#xD;
To evaluate the efficacy of Clemastine relative to placebo at reducing radial diffusivity derived from diffusion tensor imaging as assessed by magnetic resonance imaging (MRI) during the period of exposure to active medication.</description>
        <time_frame>Treatment start to treatment end, up to 3 months.</time_frame>
        <population>MRI done at baseline, month 3, month 5</population>
        <group_list>
          <group group_id="O1">
            <title>Clemastine</title>
            <description>Participants who received Clemastine 4mg tablet twice daily in either the first 3 months or the last 2 months of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Placebo (matching clemastine 4mg tablet) in either the first 3 months or the last 2 months of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Myelin Water Fraction (MWF) and Magnetization Transfer Ratios (MTR)</title>
          <description>To evaluate the efficacy of Clemastine relative to placebo in increasing magnetization transfer ratios derived from magnetic resonance imaging (MRI) of the brain during the period of exposure to active treatment.&#xD;
To evaluate the efficacy of Clemastine relative to placebo at reducing radial diffusivity derived from diffusion tensor imaging as assessed by magnetic resonance imaging (MRI) during the period of exposure to active medication.</description>
          <population>MRI done at baseline, month 3, month 5</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MTR 25: full brain at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0,380" spread="0.040"/>
                    <measurement group_id="O2" value="0.379" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MTR: white matter at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.533" spread="0.018"/>
                    <measurement group_id="O2" value="0.533" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MWF 50 at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.38" spread="13.06"/>
                    <measurement group_id="O2" value="66.12" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MTR 25: full brain change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.016"/>
                    <measurement group_id="O2" value="-0.009" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MTR: white matter change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.021"/>
                    <measurement group_id="O2" value="-0.004" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MWF 50 change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="13.20"/>
                    <measurement group_id="O2" value="-0.55" spread="10.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Expanded Disability Status Scale (EDSS) Score</title>
        <description>To evaluate the efficacy of Clemastine relative to placebo in reducing the EDSS score at 90 days compared to placebo (Group A) &amp; at 150 days compared to day 90 (Group B). EDSS is an ordinal scale for assessing neurological impairment of MS based on a neurological examination. It consists of scores in each of seven functional systems (FS) &amp; an ambulation score that are then combined to determine the EDSS [ranging from 0 (normal) to 10 (death due to MS)]. The FSs are the Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel &amp; Bladder, &amp; Cerebral functions. FSs &amp; EDSS steps assessed in a standardized manner. EDSS is a widely used &amp;accepted instrument to evaluate disability status at a given time &amp; longitudinally, to assess disability progression in clinical studies in MS.</description>
        <time_frame>Start of treatment to end of treatment, up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clemastine</title>
            <description>Participants who received Clemastine 4mg tablet twice daily in either the first 3 months or last 2 months of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Placebo (matching Clemastine 4mg) in either the first 3 months or last 2 months of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Expanded Disability Status Scale (EDSS) Score</title>
          <description>To evaluate the efficacy of Clemastine relative to placebo in reducing the EDSS score at 90 days compared to placebo (Group A) &amp; at 150 days compared to day 90 (Group B). EDSS is an ordinal scale for assessing neurological impairment of MS based on a neurological examination. It consists of scores in each of seven functional systems (FS) &amp; an ambulation score that are then combined to determine the EDSS [ranging from 0 (normal) to 10 (death due to MS)]. The FSs are the Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel &amp; Bladder, &amp; Cerebral functions. FSs &amp; EDSS steps assessed in a standardized manner. EDSS is a widely used &amp;accepted instrument to evaluate disability status at a given time &amp; longitudinally, to assess disability progression in clinical studies in MS.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EDSS at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="1.21"/>
                    <measurement group_id="O2" value="2.14" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EDSS change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.87"/>
                    <measurement group_id="O2" value="-0.03" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Creatinine Level</title>
        <description>Blood sample will be collected at each visit to evaluate health status...</description>
        <time_frame>Baseline, 1 month, 3 month, 5 month</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Triglyceride Level</title>
        <description>Blood sample will be collected at each visit to evaluate health status.</description>
        <time_frame>Baseline, 1 month, 3 month, 5 month</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vitamin B-12 Level</title>
        <description>Blood sample will be collected at each visit to evaluate health status.</description>
        <time_frame>Baseline, 1 month, 3 month, 5 month</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Human Chorionic Gonadotropin (hCG) Level in Female Patients of Childbearing Potential</title>
        <description>Blood and urine sample will be collected to assess pregnancy status of all female participants of child bearing potential.</description>
        <time_frame>Baseline, 1 month, 3 month, 5 month</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 5 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clemastine</title>
          <description>Participants received Clemastine 4mg twice daily for either 3 months or 2 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received Placebo (matching Clemastine 4mg) for either 3 months or 2 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased trigylcerides</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Severe fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tracy Tran, BA</name_or_title>
      <organization>UCSF</organization>
      <phone>415-353-2707</phone>
      <email>tracy.tran@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

